Announced Tue, 7 Jul · 10:15 IST
Ajanta Pharma submits Q1 FY27 dematerialization certificate to exchanges
Compliance View source PDF
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-2.7%1-day move
₹3375.00
prior close
₹3312.70
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2-0.5-0.2-0.0-2.7-2.1-0.3+1.5+1.2+2.3————
Up moveDown movePending
AI summary
Ajanta Pharma has filed a certificate from its registrar MUFG Intime India with BSE and NSE under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The certificate confirms that all securities received from depository participants for dematerialization were duly processed, with original share certificates mutilated and cancelled, and the depositories recorded as registered owners within the required timelines. This is a routine quarterly compliance requirement with no business action involved.
Likely market impact
Routine regulatory compliance filing, no material impact on shareholders or stock price.